

1 **Longitudinal analyses after COVID-19 recovery or prolonged infection reveal**
2 **unique immunological signatures after repeated vaccinations**

3

4 **Authors**

5 Daisuke Hisamatsu^{1,*}, Akari Ikeda¹, Lisa Ito¹, Yasushi Matsushita², Makoto Hiki³, Hirotake Mori⁴,
6 Yoko Tabe⁵, Toshio Naito⁴, and Chihiro Akazawa^{1,†,*}

7

8 **Affiliations**

9 ¹Intractable Disease Research Center, Juntendo University Graduate School of Medicine, Tokyo,
10 Japan

11 ²Department of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University
12 School of Medicine, Tokyo, Japan

13 ³Department of Cardiovascular Biology and Medicine, Juntendo University School of Medicine,
14 Tokyo, Japan

15 ⁴Department of General Medicine, Juntendo University School of Medicine, Tokyo, Japan

16 ⁵Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine,
17 Tokyo, Japan

18 [†]Lead contact

19 *Corresponding authors: Correspondence and requests for materials should be addressed to
20 d.hisamatsu.ap@juntendo.ac.jp (DH) and c.akazawa.gt@juntendo.ac.jp (CA).

21 Please address correspondence to: Chihiro Akazawa, MD, Ph.D.

22 Intractable Disease Research Center

23 Juntendo University Graduate School of Medicine

24 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

25 Tel: +81-3-5802-0439

26 E-mail: c.akazawa.gt@juntendo.ac.jp

27

28 **Conflict of interest statement**

29 The authors have declared that no conflict of interest exists.

30

31 **Abstract**

32 **Background:** To strategically develop preventive and therapeutic measures against coronavirus
33 disease 2019 and its causative virus, SARS-CoV-2, it is critical to fully characterize immune
34 response and sustained immune activation following viral infection and vaccination. However, the
35 mechanisms controlling intrapersonal variation in antibody titers against SARS-CoV-2 antigens
36 remain unclear. To gain further insights into how we can optimize therapeutic and preventive care,
37 we performed a robust molecular and cellular investigation of immune responses in infected,
38 recovered, and vaccinated individuals.

39 **Methods:** We evaluated the expression of 29 cytokines and assessed their correlation with
40 neutralizing potency. We further investigated memory B-cell response in patients infected with the
41 original SARS-CoV-2 strain or other variants of concern, and in vaccinated individuals.

42 **Results:** Correlation analyses showed that the relationship between neutralizing activity and
43 cytokine expression differed according to disease severity and viral strain. Furthermore, long-term
44 longitudinal analyses revealed that post-vaccination neutralizing potential was more strongly
45 associated with various cytokine expression levels in recovered patients than in naïve individuals.
46 Notably, we found a similar distribution of virus-specific antibody gene families in triple-
47 vaccinated individuals and a patient with COVID-19 pneumonia for one year.

48 **Conclusion:** Our results showed that distinct immune responses occur depending on the viral strain
49 suggesting that therapeutic options should be selected on a case-by-case basis. Furthermore,
50 longitudinal analyses revealed biomarker candidates that correlated with repeated vaccination that
51 may be applicable to therapies regulating specific immune responses and novel monoclonal
52 antibodies.

53 **Funding:** This work was supported by the Institutional Funds, YOKOYAMA Foundation for
54 Clinical Pharmacology (#YRY-2121), and the Japan Society for the Promotion of Science (JSPS)/
55 Ministry of Education, Culture, Sports, Science, and Technology (MEXT) KAKENHI; Grant-in-
56 Aid for Early-Career Scientists (#21K15888).

57

58 **Introduction**

59 Therapeutic options for coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
60 syndrome coronavirus 2 (SARS-CoV-2) infection, include convalescent plasma therapy, antiviral
61 drugs, and monoclonal antibody therapy. However, these strategies have not changed since their
62 development in 2019, when the original SARS-CoV-2 strain emerged despite the fact that multiple
63 mutations have since been recorded. A major clinical challenge in treating patients with severe
64 COVID-19 is hyperactivation of the immune system, which is caused by a “cytokine storm,” that
65 is, overproduction of systemic pro-inflammatory cytokines (1, 2). Cytokine storms are thought to
66 cause multiorgan failure, but their mechanism of onset is not well understood. As of April 2022,
67 five variants of concern (VOCs) have been identified by the World Health Organization: Alpha
68 (also known as B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron
69 (B.1.1.529). These variants exhibit increased infectivity and pathogenicity along with reduced
70 sensitivity to neutralizing antibodies in comparison with the wild-type (WT) SARS-CoV-2 strain
71 (3-8). Mutations within VOCs are likely responsible for the varied immune responses induced by
72 infection. Candidates include mutations in the Spike (S) protein and its receptor-binding domain
73 (RBD), which may affect binding to human angiotensin-converting enzyme 2 (ACE2) and
74 signaling pathways induced upon cellular entry (9). Therefore, different SARS-CoV-2 strains may
75 induce different cytokine responses, such that specific cytokine profiles may be associated with
76 clinical characteristics.

77 Adequate longitudinal protection against severe COVID-19 requires more than one dose
78 of the common SARS-CoV-2 vaccines (10). Several studies have found differences in the degree
79 and duration of neutralizing antibody responses induced by different vaccines, which include
80 messenger RNA (mRNA)-based vaccines from Pfizer-BioNTech (BNT162b2) and Moderna

81 (mRNA-1273), and in the responses induced by subsequent booster vaccinations (10-13).
82 Furthermore, a study in recovered COVID-19 patients showed that a rapid antigen-specific
83 memory B-cell (Bmem) response occurs after the first vaccine dose, with serum antibody titers
84 reaching a peak value (11, 14-17). However, biomarkers to guide the repeat vaccine are unknown,
85 especially in recovered individuals.

86 The acquisition of high-affinity antibodies, a process known as affinity maturation, occurs
87 via diversification and clonal selection through somatic hypermutations (SHMs) introduced during
88 the active proliferation of antigen-stimulated B-cells in the germinal center (18). In recovered
89 COVID-19 patients, the accumulation of SHMs in antibody genes induces formation of potent and
90 broadly neutralizing antibodies that are effective against VOCs (19, 20). Compared with naïve
91 individuals, infected individuals who receive repeat vaccinations have been reported to exhibit a
92 more potent antibody response to VOCs (21). By contrast, some immunocompromised individuals
93 receiving immunosuppressive therapy such as rituximab, fail to develop anti-SARS-CoV-2
94 antibodies at the symptom onset and following repeated vaccinations (22). However, the molecular
95 basis of these immunological processes and the B-cell receptor (BCR) repertoire after infection or
96 vaccination remains unclear, particularly in patients with immunodeficiency.

97 Approximately 100 d after infection, most individuals experience a decrease in serum
98 antibody levels against SARS-CoV-2 (23, 24). Even after vaccination, the serum antibody titers
99 are low in some populations, such as immunocompromised patients and elderly participants (25,
100 26). Furthermore, the emergence of VOCs is speculated to maintain and encourage human-to-
101 human transmission and cause residual infections in immunocompromised hosts (27-30). Choi et
102 al. performed a 152-day longitudinal analysis of a patient receiving immunosuppressive therapies
103 and showed that amino acid changes were observed in 57% of S genes and 38% of RBD genes

104 (31). Furthermore, late-phase mutations seen in this patient were resistant to a common class of
105 neutralizing antibodies derived from healthy recovered COVID-19 patients and clinical
106 monoclonal antibodies (31). In such immunocompromised hosts with prolonged infection, SARS-
107 CoV-2 is thought to evolve into a new strain that is more proficient at immune evasion (29, 30, 32,
108 33). We thought antibodies produced against the new strain carrying an unknown mutation might
109 be helpful as a therapeutic monoclonal antibody.

110 In this study, we aimed to determine whether the immune response induced by SARS-
111 CoV-2 infection or vaccination is affected by infection strain and/or the presence of underlying
112 comorbidities. Furthermore, we sought to identify molecular biomarkers in individuals vaccinated
113 against SARS-CoV-2, as these may help in the management of longitudinal dosing. We
114 hypothesized that a unique Bmem response occurs in immunocompromised patients, generating
115 broadly neutralizing antibodies against new or unknown variants. To this end, we performed
116 longitudinal analyses of cytokine profiles associated with neutralizing activity, including the
117 distribution of antibody gene sequences in patients with or without comorbidities during infection
118 and after vaccination. Our work shows that sequencing of antibody genes after recovery of
119 immunocompromised patients may reveal antibody immunogenicity. Furthermore, the antibodies
120 produced by such immunocompromised patients are expected to be valuable as therapeutic
121 monoclonal antibodies.

122

123 **Results**

124 ***Characterization of serum antibodies in COVID-19 patients***

125 We initially set out to investigate serum antibody features from patients who either exhibited
126 ongoing COVID-19 or had recovered following infection during the second and third waves of
127 infection in Japan between August 2020 and March 2021, prior to the emergence of the Alpha
128 variant. In July 2021, serum samples were collected from recovered patients infected with SARS-
129 CoV-2 VOCs encoding N501Y and L452R mutations. Upon admission to the hospital, moderate
130 I patients infected with the WT strain and moderate II patients infected with VOCs displayed
131 similar clinical characteristics (Supplemental Figure 1). This difference in disease severity may be
132 due to VOC-infected patients who were classified as moderate I disease on admission, but whose
133 symptoms subsequently worsened and became classified as moderate II disease. Serum samples
134 from WT patients were analyzed for antibody binding to the S-RBD using enzyme-linked
135 immunosorbent assay (ELISA) and anti-IgG and anti-IgM antibodies. We found that patients with
136 moderate I and II illness exhibited higher IgG and IgM levels at discharge than at admission
137 (Figure 1A and 1B). Next, we evaluated the serum samples for *in vitro* neutralizing activity in
138 blocking the binding between S-RBD WT and human ACE2. Neutralizing activity was positively
139 correlated with serum anti-S-RBD IgM and IgG levels in all patients (Spearman's correlation
140 coefficient: 0.66, and 0.76, respectively; Figure 1C). The neutralizing activity tended to be
141 positively correlated with age in all the samples of the population (coefficient: 0.15) and appeared
142 to be sex-independent (Figure 1D and 1E). We then examined the neutralizing activity of sera from
143 patients infected with VOCs via binding assays specific for the RBD domains of the WT, Kappa
144 (formerly one of variants of interest), and Delta strains. Neutralizing potential against the WT
145 strain was positively correlated with disease severity (Figure 1F). Patients who eventually died

146 exhibited low neutralizing activity against the WT strain; however, one patient exhibited high
147 activity against the Kappa and Delta variants (67.9% and 51.1%, respectively; Figure 1G and 1H).
148 These data suggest that the generation of neutralizing antibodies against the infecting strain was
149 necessary for recovery. Notably, we found that the polyclonal neutralizing antibody response in
150 infected patients extended to strains beyond those responsible for the primary infection. Moderate
151 II patients infected with the WT strain, excluding deceased patients, developed a higher
152 neutralizing potency against the WT and variant strains than that observed in patients infected with
153 VOCs containing the L452R mutation (Figure 1G and 1H). The mean value of neutralizing activity
154 against the WT strain was 47.1% in WT-infected patients and 25.8% in VOC-infected patients (p
155 = 0.044). For WT- and VOC-infected individuals, neutralizing activity was 53.6% and 25.4%
156 against Kappa ($p = 0.045$) and 40.1% and 18.6% against Delta, respectively ($p = 0.05$; Figure 1G
157 and 1H).

158 *Serum cytokine features of COVID-19 patients infected with WT and VOC strains*

159 To characterize the cytokine response induced by different SARS-CoV-2 strains, we determined
160 and compared the protein expression of 29 cytokines and chemokines in the sera of patients
161 infected with WT and VOC strains at admission and discharge using a flow cytometric bead array
162 (Supplemental Figure 2 and Supplemental Figure 3). Upon discharge, serum levels of CCL2, a
163 biomarker known to correlate positively with mortality risk in COVID-19 patients (34), trended
164 slightly lower in mild and moderate I patients than in moderate II patients (Figure 2). Although
165 CCL5 and CCL11 levels in patients infected with the WT strain tended to be higher at discharge
166 than at admission, the CCL11 levels at discharge in patients infected with VOCs were much higher
167 than those at admission ($p = 0.057$) and those in moderate II patients infected with WT at discharge
168 ($p = 0.03$). By contrast, serum levels of IL-6, CXCL10, and CXCL11 tended to be higher at

169 admission than at discharge for all WT and VOC disease severities. Serum Fas ligand levels were
170 inversely correlated with severity (Figure 2). In the two patients from our cohort who died during
171 the experimental period, serum IL-6, IL-8, and CCL2 levels were more elevated than those in
172 survivors (Supplemental Figure 2).

173 Next, we compared serum cytokine levels upon admission between the WT and VOC-
174 infected patient groups (Supplemental Figure 4). The time from onset of symptoms to blood
175 collection was similar (WT 8.3 ± 4.1 d, VOCs 8.0 ± 2.8 d). We found that the serum levels of IFN-
176 α , IL-13, IL-10, and CCL11 were higher in VOC-infected patients than in WT-infected individuals,
177 whereas IL-5 and IL-4 were higher in WT-infected patients than in those with VOCs. These data
178 suggest that different immune responses occurred during infection with mutant and WT strains.

179 ***Correlation analysis of serum cytokines and neutralizing activity in COVID-19 patients***

180 Next, we investigated the correlation between neutralizing activity against WT and serum cytokine
181 levels. Spearman's correlation coefficient analysis showed a negative correlation between
182 neutralizing activity and serum levels of most cytokines in all patients and within each severity
183 group. Specifically, CXCL10, CXCL11, IL-6, and IL-10 serum levels showed strong negative
184 correlations with neutralizing activity in patients with moderate I and II disease (Figure 3A and
185 3B). This result is consistent with the reduction of acute inflammation caused by infection.
186 Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating
187 factor (GM-CSF) serum levels were negatively correlated with neutralizing activity only in
188 moderate II patients infected with VOCs. We found that the serum levels of CCL11 and IL-5 were
189 positively correlated with neutralizing activity, regardless of disease severity. IL-4 serum
190 concentrations were positively correlated with neutralizing activity in patients with mild disease
191 (Figure 3A). These cytokines play an important role in activating and mobilizing eosinophils

192 during allergic response (35). Next, we assessed the correlation between patient age, cytokine
193 expression, and neutralizing activity (Supplemental Figure 5). Patient age was positively and
194 significantly correlated with serum levels of IL-6, IL-8, MIG, and G-CSF (coefficients: 0.46, 0.40,
195 0.43, and 0.33, respectively). Patient age was negatively and significantly correlated with serum
196 levels of Fas ligand (coefficient: -0.45), as was serum neutralizing activity against WT (coefficient:
197 -0.36). Furthermore, a strong positive correlation was observed between the serum levels of
198 CXCL11, CXCL10, MIG, IL-6, IL-8, and IL-10 (Supplemental Figure 5).

199 ***Distinct immune response in recovered patients and naïve individuals after mRNA vaccination***

200 To identify the changes in cytokine expression associated with increased neutralizing activity after
201 mRNA-based COVID-19 vaccinations, we first investigated serum neutralizing activity in
202 uninfected individuals and in those who recovered from WT infection. Sera were collected
203 following their first and second vaccinations with mRNA-based vaccines BNT162b2 or mRNA-
204 1273. WT-infected individuals had been infected 130 ± 5.4 d prior to vaccination. Sera were
205 obtained from uninfected and WT-infected individuals at 14.0 and 17.3 ± 2.0 d after the first dose
206 and at 24.5 ± 2.1 and 27.0 ± 6.7 d after the second dose, respectively. The neutralizing activity
207 against the WT, Kappa, and Delta strains reached a peak after the first dose in the recovered patient
208 group, except in one patient with mild disease (Figure 4A). Following the second dose, naïve and
209 recovered patients exhibited significantly higher neutralizing activities than those seen before
210 vaccination, with a slightly stronger potency in recovered than in naïve patients (mean value: naïve
211 41.7%, recovered 57.8% against WT; naïve 61.1%, recovered 96.0% against Kappa; naïve 67.0%,
212 recovered 95.7% against Delta; Figure 4A).

213 To investigate the role of cytokines in mediation of immune responses following
214 vaccinations, we performed a comprehensive analysis of 29 cytokine levels in the sera. The

215 changes in cytokine levels after vaccination showed a specific trend, but significant differences
216 were not observed because of the high interpersonal pre-vaccination variation in cytokine levels
217 (Figure 4B). Specifically, serum IL-12p40 levels were elevated above pre-vaccine levels after the
218 first dose and decreased after the second dose in both naïve and recovered patient groups. By
219 contrast, the opposite was observed for serum CCL5 levels, which decreased after the first dose
220 and increased after the second dose (Figure 4B). Serum levels of the Fas ligand, CXCL10, and
221 CCL2 were slightly decreased after vaccination (Figure 4B). Interestingly, the mean serum levels
222 of CXCL11 among naïve and recovered patient cohorts prior to vaccination were similar, but the
223 recovered patients exhibited significantly higher CXCL11 serum levels post-vaccination.

224 We then examined whether correlations existed between neutralizing activity and cytokine
225 expression and among individual cytokines in naïve and recovered patients. We observed a slight
226 positive correlation between IL-8 and IL-10 expression and neutralizing activity against WT,
227 Kappa, and Delta strains in recovered patients (coefficient: IL-8 vs. Kappa 0.55; IL-10 vs. WT
228 0.57; IL-10 vs. Kappa 0.55; IL-10 vs. Delta 0.57; Figure 4C). Although serum CXCL10 and
229 CXCL11 levels were negatively correlated with neutralizing activity upon infection (Figure 3A
230 and Supplemental Figure 5), post-vaccination levels tended to be positively correlated in the
231 recovered patient group (Figure 4C). Conversely, uninfected individuals showed a negative
232 correlation trend similar to that of the recovered patient group upon infection. Across the entire
233 group, serum levels of IL-8, IL-10, and CXCL11 were positively correlated with neutralizing
234 activity (Supplemental Figure 6). Post-vaccination IL-8 and Fas ligand levels were negatively
235 correlated with each other in the naïve group and during initial infection of recovered patients but
236 showed a positive correlation in recovered individuals (Figure 4C and Supplemental Figure 5).

237 Altogether, the difference in cytokine expression changes between the naïve and recovered patient
238 groups suggests that a unique immune response occurred after vaccination in recovered individuals.

239 *Antigen-specific memory B-cell response in a COVID-19 patient with high neutralizing potency*
240 *after vaccination*

241 Long-term observation of a single group of patients for more than one year is needed to clarify the
242 number of repeat COVID-19 vaccine doses required for recovered individuals. To determine the
243 changes in neutralizing activity in recovered patients following booster vaccination, we performed
244 longitudinal analyses of neutralizing activity and SARS-CoV-2-specific Bmem in peripheral blood
245 following infection and vaccination. In our cohort, most patients showed an increase in
246 neutralizing activity at discharge, but one showed a drop. Because all patients were initially
247 infected and the time to admission from onset did not differ (data not shown), we excluded this
248 patient from our cohort. In order to examine patients who have recovered with their neutralizing
249 antibodies, we selected a representative healthcare worker infected with the WT strain who
250 exhibited moderate II disease with high neutralizing activity upon infection (indicated by # in
251 Figure 1F). This patient withdrew from treatment with an antiviral drug, favipiravir, because of its
252 side effects and recovered only with nasal high-flow oxygen therapy. He was discharged on day
253 23 of hospitalization after a negative reverse transcription polymerase chain reaction (RT-PCR)
254 test result. During the follow-up period, two vaccine doses were administered, one (BNT162b2)
255 on day 273 and the second (BNT162b2) on day 297. The third booster dose (BNT162b2) was
256 administered on day 495 after infection onset. We designated the time of medical examination as
257 “before infection” and the time of appearance of symptoms upon infection as “day zero”. In this
258 patient, serum IgM and IgG levels peaked 10 and 20 d after symptom onset, respectively (Figure
259 5A). Neutralizing activity against the WT strain mirrored the IgG response, peaking at 20 d

260 (inhibition rate: 55.4%) and decreasing to half its peak after 82 d (inhibition rate: 23.4%; Figure
261 5B). By day 185, the neutralizing activity against the WT strain returned to the level observed
262 before infection. Interestingly, neutralizing activity against the Delta variant gradually increased
263 from day 10 post-infection and reached 44.7% on day 185 (Figure 5B). Fourteen days after the
264 first vaccine dose, neutralizing activity against the WT strain reached 55.8%, close to the peak at
265 the time of infection, and reached a peak value 7 d after the second dose of vaccination (Figure
266 5B). The neutralizing activity gradually decreased to 19.0% after four months, and this level was
267 maintained until the third vaccine dose (Figure 5B). By contrast, neutralizing activities against
268 Delta and Kappa variants peaked 7 d after the first dose and remained high before and after the
269 third vaccination (Figure 5B).

270 To investigate whether this fluctuation in neutralizing activity is associated with virus-
271 specific Bmems, we performed fluorescence-activated cell sorting (FACS) analysis of peripheral
272 blood mononuclear cells (PBMCs). The proportion of the IgG⁺CD19⁺CD27⁺ Bmem population
273 increased after the second dose in the recovered individual. In particular, the CD19⁺CD27⁺ cell
274 population showed a remarkable increase after the second and third vaccinations compared to that
275 seen 272 d after onset (1.6- and 1.8-fold, respectively; Figure 5C and 5F). The percentage of
276 Bmems binding to the recombinant S-RBD WT protein showed little change from onset to day 42
277 after the second vaccination but increased 2.86-fold after the third dose (Figure 5C). The absolute
278 number of IgG⁺S-RBD⁺ Bmems and the percentage of lymphocytes were elevated after the first
279 and third doses (Figure 5D and 5E). Notably, on day 272 from onset, the proportion of IgG⁺S-
280 RBD⁺ Bmems and CD38^{high} plasma cells was slightly higher than that on day 73, yet the
281 neutralizing activity against the WT strain had almost disappeared (Figure 5B, 5C, and 5F). These

282 results suggest that serum neutralizing activity did not coincide with the cellular dynamics of virus-
283 specific Bmems.

284 ***Longitudinal cytokine profiles reveal a unique immune response after repeated vaccination***

285 We found that intrapersonal neutralizing activity against the WT strain gradually decreased both
286 after the initial infection and after vaccination. By contrast, neutralizing activity against the Delta
287 variant gradually increased after the initial infection and peaked after vaccination (Figure 5B). To
288 gain insight into how immune responses mediate this phenomenon, we performed a longitudinal
289 study on the effects of infection and mRNA-boosted vaccination on serum cytokine levels in the
290 individual patient under long-term observation. Serum IL-6, IL-10, IL-12p40, G-CSF, CXCL10,
291 and CXCL11 levels considerably increased starting on day 6 and diminished between days 10 and
292 20 (Figure 6A). CCL5 serum levels gradually increased and peaked by day 82, a pattern similar to
293 that of serum neutralizing activity against the WT strain (Figure 5B and 6A). On day 27, serum
294 levels of IL-6 and IL-12p40 were transiently elevated. Intriguingly, serum levels of G-CSF
295 remained high from day 27 to day 185. Notably, serum levels of IL-6, IL-8, IL-13, IL-12p40,
296 CCL5, CXCL10, and CCL2 were markedly elevated for 3–7 d after each vaccination. We found
297 that transient upregulation of CCL2 and CXCL10 expression was highest after the first dose, and
298 repeated vaccination diminished this response (Figure 6A).

299 We then examined longitudinal serum cytokine levels from the patient and compared them
300 against serum neutralizing activity to identify potential correlations. We divided the time from
301 onset of symptoms to 185 days as an “infection,” and from one day before the first dose to 36 days
302 after the third dose as a “vaccination.” In the case of infection, neutralizing activity against the WT
303 strain exhibited a significant positive correlation with CCL5 (coefficient: 0.73, $p = 0.02$) and a
304 negative correlation with G-CSF levels (coefficient: -0.69, $p = 0.03$; Figure 6B). In the case of

305 vaccination, the neutralizing activity against WT was significantly positively correlated with IL-
306 10 levels (coefficient: 0.67, $p = 0.009$; Figure 6B). Correlations among individual cytokines
307 differed between the infection and vaccination periods. Our findings that specific cytokines were
308 released during vaccination and that transient elevation of CCL2 and CXCL10 levels was
309 diminished by repeated vaccination suggest that the immune response may have been attenuated
310 by repeat vaccination.

311 ***Affinity maturation by the third booster vaccination and the natural development that occurred***
312 ***in prolonged COVID-19 patient are uniform***

313 The relative percentage of Bmems binding to the recombinant S-RBD WT showed little change
314 from onset to after the second vaccination, but the neutralizing activity against the WT strain
315 showed transient upregulation (Figure 5B and 5C). To determine whether this change in
316 neutralizing activity resulted from affinity maturation, IgG⁺S-RBD⁺ Bmems were single-cell
317 sorted, and their antibody genes were sequenced. The distributions of both heavy and light chain
318 antibody genes were skewed toward specific families on day 272 from onset, but several types of
319 antibody genes were observed (Figure 7A). After the second vaccination, a completely different
320 gene family, immunoglobulin heavy chain variable (IGHV) 4-61*02/IGHV4-61*09, was
321 selectively observed over 272 days in the heavy chain analysis (Figure 7A). Light chain analysis
322 revealed that the minor gene family, immunoglobulin light chain (IGLV) 1-44*01, present at
323 disease onset became a prominent family following the second vaccination (Figure 7B).
324 Remarkably, new families emerged in the heavy and light chains following the third booster
325 vaccination. These data suggest that booster vaccination elicited affinity maturation of S-RBD
326 WT-specific Bmem antibody genes, consistent with the long-term maintenance of neutralizing
327 activity against VOCs in the recovered patient.

328 Finally, we examined the effect of prolonged infection on affinity maturation in an
329 immunocompromised patient who developed COVID-19 pneumonia during rituximab
330 maintenance treatment for follicular lymphoma, with lung lesions persisting for one year. Notably,
331 the patient failed to develop anti-SARS-CoV-2 antibodies throughout the disease course
332 (Supplemental Figure 7A), and the products used for immunoglobulin replacement therapy
333 contained no anti-SARS-CoV-2 antibodies, suggesting that recovery from COVID-19 pneumonia
334 was not due to patient-derived humoral immunity or external antibody supplementation (22, 36).
335 To gain deeper insight into the effect of immunocompromise on affinity maturation, we performed
336 sequencing of the antibody genes expressed during recovery in this patient and compared them to
337 those from a WT-infected patient observed over time. Antibody-producing cells were isolated from
338 PBMCs collected one year after infection. Although we had previously examined the antibody
339 genes of IgG⁺S-RBD⁺ Bmems, we evaluated the CD19⁺CD27⁺IgG⁺ cell antibody gene because
340 the S-RBD⁺ cell population was absent in the immunocompromised patient with prolonged
341 COVID-19 (Supplemental Figure 7B, 7C, and 7D). Intriguingly, we found that a major proportion
342 of the IGHV4-61*02/IGHV4-61*09 and IGLV1-44*01 antibody gene families that emerged after
343 the second vaccination, as well as a minor population comprising IGHV4-61*09 and IGLV1-
344 44*01/IGLV1-44*03 that arose after the third dose in the recovered individual, were also present
345 in the patient with prolonged COVID-19 (Figure 7A and 7B). To further characterize these
346 antibody genes, we evaluated SHMs and the length of complementary-determining region 3
347 (CDR3). In the heavy and light chains of the recovered individual, the number of SHMs was
348 significantly lower after the second or third vaccination than at 272 days from onset ($p < 0.005$;
349 Figure 7C). In the immunocompromised patient with prolonged COVID-19, the number of SHMs
350 in the heavy chain at one year from onset was significantly lower than that at 272 days from onset

351 in the recovered individual but did not differ from post-vaccination levels in the recovered
352 individual. By contrast, the SHM abundance in the light chain of the patient with prolonged
353 COVID-19 did not differ at 272 days from the onset in the recovered individual but was
354 significantly higher than that after the second or third vaccination ($p < 0.005$ and $p = 0.007$,
355 respectively; Figure 7C). Although the length of CDR3 on the heavy chain was skewed after
356 vaccination in the recovered patient, variable lengths were observed in the immunocompromised
357 patient with prolonged COVID-19 (Figure 7D). By contrast, the light chain lengths in the
358 recovered individual after the onset and vaccination and in the immunocompromised patient with
359 prolonged COVID-19 trended toward 33 nucleotides (Figure 7D).

360 To investigate the immune response during infection in immunocompromised patients, we
361 examined serum cytokine levels in the patient with prolonged COVID-19 at 17 and 71 d from the
362 onset of infection. We found that IL-17F, which is involved in chronic inflammation and
363 autoimmune diseases (37), was present in the serum, although it was not observed in other COVID-
364 19 patients (Supplemental Figure 8). These results suggest that this immunocompromised patient
365 exhibited a distinct immune response upon infection compared to WT- or VOC-infected patients.

366

367

368 Discussion

369 This study highlights, for the first time, that the distribution of the BCR repertoire after COVID-
370 19 vaccination in recovered patients is similar to that of antibody gene families observed in a
371 patient with long-term infection owing to immunosuppressive therapy with rituximab. The Bmem
372 responses in this patient were similar to those seen after three-dose vaccination in healthy
373 recovered participants. Although our findings supported the notion that immunocompromised
374 patients do not produce anti-SARS-CoV-2 antibodies, they revealed evidence of affinity
375 maturation in CD19⁺CD27⁺ B-cells with low IgG expression. Furthermore, we found a candidate
376 molecular biomarker that correlates with neutralizing activity in the characteristic immune
377 response of recovered individuals after repeated vaccination.

378 Immunocompromised hosts receiving convalescent plasma therapy, immunoglobulin
379 replacement therapy, or antiviral drugs exhibit aberrant mutations in the SARS-CoV-2 genome
380 that could trigger viral evolution (32). Because our immunocompromised patient underwent
381 immunoglobulin replacement therapy for one year (22, 36), suggesting that the viral genome may
382 contain more mutations. The immunocompromised patient infected with the WT strain exhibited
383 antibody gene sequences similar to those of post-vaccination antibodies in recovered patients with
384 broadly neutralizing antibodies (Figure 7A and 7B). Furthermore, we identified antibody genes
385 IGHV4-31*03 and IGHV4-59*01 in this patient and in moderate II patients infected with the Delta
386 strain (data not shown), but not during infection or after vaccination in mild or moderate II patients
387 infected with the WT strain. This is particularly interesting considering the value of therapeutic
388 monoclonal antibodies because it suggests that immunocompromised patients generate broadly
389 neutralizing antibodies against new variants created in the body. Collectively, our findings suggest
390 that the determination of few antibody gene sequences in recovered patients with

391 immunodeficiencies is effective for producing clinical antibodies. The antibodies we discovered
392 may exhibit broad neutralizing potency against unknown strains arising in the future.

393 To maximize the efficacy of therapeutics and vaccines, it is important to identify molecular
394 biomarkers from the immune profile of each variant strain after infection or longitudinal dosing of
395 the vaccine. We observed a markedly higher expression of IFN- α upon admission in VOC-infected
396 patients compared to that in WT-infected patients (Supplemental Figure 4). IFN- α is a type I
397 interferon, a type of cytokine involved in antiviral responses (38). The variant, including the Delta
398 strain, enhances pathogenicity more than the ancestral strain (8), probably resulting in elevated
399 IFN- α expression in VOC-infected patients. We further found differences in serum levels of IL-4,
400 IL-5, IL-10, and IL-13 between WT- and VOC-infected patients (Supplemental Figure 4). These
401 cytokines, mainly produced by eosinophils and basophils, contribute to T-helper 2 (Th2) responses
402 involved in allergic reactions and antibody production (35, 39), suggesting that the degree of Th2
403 response differs by the infectious strains. Pavel et al. demonstrated the interaction between IFN- γ -
404 producing Th1 and Th2 in a high-risk group for severe COVID-19 disease, suggesting that
405 Th1/Th2 cytokine imbalance is associated with higher mortality (40). Several studies have shown
406 that adjuvants, a key component of certain inactivated vaccines and antiviral drugs, induced robust
407 and long-lasting specific immune responses, and those of inactivated coronavirus vaccines
408 adjusting the Th1/Th2 balance are more effective without side effects (41). Altogether, considering
409 the attenuated efficacy of some antiviral drugs and therapeutic monoclonal antibodies against the
410 Omicron strain (42, 43), our findings suggest that the variants and unknown strains may be best
411 treated using adjuvants that regulate the Th1/Th2 balance.

412 Takano et al. evaluated immune parameters, such as cytokine expression and cellular
413 dynamics, that correlate with antibody response and systemic adverse events after two doses of an

414 mRNA vaccine, revealing higher neutralizing activity and rates of systemic adverse events in a
415 naïve patient group with high expression of IFN- γ , CCL2, CXCL9, and CXCL10 (44). This finding
416 is consistent with our results of a positive correlation between serum IL-10 level and neutralizing
417 activity over 300 days, and with the observed transient upregulation of serum CCL2, CXCL10,
418 and IL-12p40 levels from 3–7 d after each vaccination (Figure 6A and 6B). By contrast, we found
419 distinct differences in cytokine expression associated with neutralizing activity between naïve and
420 recovered patients following vaccinations (Figure 4C). Given the asymptomatic infection that is
421 one of the hallmarks of SARS-CoV-2, it is crucial to explore parameters in recovered patients, and
422 our results support the possibility that IL-10 may be useful as a candidate biomarker.

423 This study had several limitations. First, our cohort comprised a small sample population.
424 It is therefore impossible to determine whether the results observed by sequencing antibody genes
425 in the immunocompromised patient was a unique characteristic of this patient or a phenomenon
426 representative of immunocompromised patients in general. To this end, we must further investigate
427 the antibody gene sequences of other immunocompromised patients who had COVID-19 and
428 compare with their post-vaccination sequences. Second, a cohort selection bias existed: inability
429 to match age or time of hospitalization due to hospital conditions at the time of admission affected
430 comparisons between groups. This resulted in differences in duration of hospitalization and age
431 between WT- and VOC-infected patients with moderate II disease. It is important to use cohorts
432 from multiple institutions matched for cofounders to precisely identify immune response
433 differences by infectious strains. Finally, we explored only the characteristic substitutions of each
434 variant, without accounting for potential unexpected mutations. Our results showed distinct
435 immune responses according to infectious strain, suggesting that the therapeutic regimen
436 developed for WT SARS-CoV-2 may be less effective against variants. In order to maximize

437 therapeutic efficacy, it is necessary to perform whole-genome sequencing of and conduct detailed
438 studies on infected strains and immune responses. Collectively, our longitudinal, in-depth analyses
439 of immune profiles in response to SARS-CoV-2 infection or vaccination, including
440 characterization of the infected viral genome and sequencing of virus-specific antibody genes, will
441 be useful to inform biomarker identification and novel therapeutic development to treat emerging
442 SARS-CoV-2 variants.

443 **Methods**

444 *Study design*

445 Patients were recruited at the Juntendo University Hospital in Tokyo, Japan, between August 2020
446 and January 2021. Study participants were adults aged 21–86 years diagnosed with COVID-19 by
447 using real-time RT-PCR for nasopharyngeal swabs using LightMix Modular SARS-CoV
448 (COVID19) N-gene and E-gene assays (Roche Diagnostics, Tokyo, Japan) according to
449 manufacturer instructions. The severity of COVID-19 was classified according to the Japan
450 Ministry of Health, Labor, and Welfare criteria. Briefly, mild cases were defined by mild clinical
451 symptoms such as cough and fever without pneumonia, according to imaging examinations. The
452 moderate cases were divided into two categories: moderate I was defined by mild respiratory
453 symptoms with pneumonia according to imaging examination, and moderate II was defined by
454 pneumonia on imaging with respiratory insufficiency and oxygen saturation $\leq 93\%$ in a resting
455 state. Healthy controls were volunteers who visited Juntendo University Hospital between August
456 and December 2020 and provided a negative RT-PCR test before blood collection. Blood samples
457 were collected at admission and discharge, and convalescent sera samples were collected during
458 outpatient follow-up after discharge.

459 *Measurement of anti-SARS-CoV-2 S-RBD IgM and IgG antibodies*

460 The levels of anti-SARS-CoV-2 S-RBD-specific IgM and IgG antibodies in serum samples were
461 determined using the IgM for SARS-CoV-2 S-RBD ELISA Kit (Proteintech, Rosemont, IL, USA)
462 and the anti-SARS-CoV-2 S-RBD protein Human IgG ELISA Kit (Proteintech) according to
463 manufacturer instructions. All serum samples were diluted 1:100 and assays were performed in
464 duplicate.

465 ***In vitro neutralization assay***

466 The following kits were used to measure the neutralizing potency against each strain following
467 manufacturer instructions: SARS-CoV-2 Neutralization Antibody Detection Kit (Medical and
468 Biological Laboratories, Tokyo, Japan) for the WT SARS-CoV-2 strain, SARS-CoV-2
469 Neutralizing Antibody Detection Kit (B.1.617.1 Variant, Kappa; AdipoGen Life Sciences, San
470 Diego, CA, USA) for the Kappa variant, and SARS-CoV-2 Neutralizing Antibody Detection Kit
471 (B.1.617.2 Variant, Delta; AdipoGen Life Sciences) for the Delta variant. The absorbance of each
472 well was measured using a Multiskan Fc with an incubator (Thermo Fisher Scientific, Waltham,
473 MA, USA). All serum samples were frozen at -80°C once after collection and were analyzed in
474 duplicate.

475 ***Cytometric bead array***

476 The expression of serum cytokines was determined using a BD™ Cytometric Bead Array Flex Kit
477 (BD Biosciences, Franklin Lakes, NJ, USA) according to manufacturer instructions. All serum
478 samples were diluted 1:6 and analyzed in duplicate. All data were analyzed on a BD FACS Verse
479 Flow Cytometer (BD Biosciences) with FCAP Array Software v3.0 (BD Biosciences) according
480 to manufacturer instructions.

481 ***Isolation of PBMCs***

482 PBMCs were isolated using 8 mL of whole blood collected from COVID-19 patients after recovery
483 and healthy volunteers using BD Vacutainer CPT tubes (BD Biosciences) according to the
484 manufacturer instructions.

485 ***Single-cell sorting by flow cytometry***

486 Isolated PBMCs were incubated with His-tagged SARS-CoV-2 S-RBD recombinant protein (Cell
487 Signaling Technology, Danvers, MA, USA) for 30 min on ice. Cells were washed using phosphate-
488 buffered saline (Nacalai Tesque, Kyoto, Japan) with 4% fetal bovine serum (Thermo Fisher
489 Scientific) before staining with a fluorescence-conjugated antibody cocktail for 30 min on ice. The
490 following antibodies were used; CD3 (SK7), CD4 (SK3), CD8 (RPA-T8), CD56 (B159), CD11b
491 (D12), CD19 (HIB19), CD27 (O323), CD38 (HIT2), and human IgG (G18-145), all from BD
492 Biosciences; FITC-conjugated His tag antibody from Abcam (Cambridge, UK); and anti-CD27
493 from BioLegend (San Diego, CA, USA). S-RBD-specific Bmems were defined as CD3⁻CD4⁻CD8⁻
494 CD56⁻CD11b⁻CD19⁺CD27⁺IgG⁺His⁺ live cells. Single cells were sorted using a FACS AriaII
495 instrument (BD Biosciences) into 96-well plates containing 4 µL/well of 8U RNAsin (Promega,
496 Madison, WI, USA), 4U of recombinant RNase inhibitor (Takara Bio, Shiga, Japan), 10 mM DTT
497 (Promega), and 10× PBS. All data were analyzed using the FlowJo software (TreeStar).

498 ***Single-cell RT-PCR and immunoglobulin gene sequencing***

499 IGHV- and IGLV-related genes were amplified using RNA ligase-mediated and oligo-capping
500 rapid amplification of cDNA ends with the GeneRacer™ Kit (Thermo Fisher Scientific) following
501 manufacturer instructions, and the PCR product was obtained as described previously with slight
502 modifications (45). Briefly, the first step of PCR was performed according to the KOD FX Neo
503 DNA polymerase guidelines (TOYOBO, Osaka, Japan). Nested PCR was performed in the same
504 manner to improve specificity to the variable region, and after PCR purification using a QIAquick
505 PCR Purification Kit (Qiagen, Hilden, Germany), the PCR product was sequenced using the
506 reverse primer used for nested PCR using Sanger sequencing (Azenta Life Science, Tokyo, Japan).
507 All primers were used as described in Supplemental Table.

508 ***Statistics***

509 A minimum of three independent experiments were included in each statistical analysis. Statistical
510 significance was determined using the tests indicated in the figure legend. Statistical significance
511 was set at $p < 0.05$. A standard curve was generated for each set of samples using a four-parameter
512 logistic curve fit. All analyses were performed using the statistical programming software R
513 version 4.0.3 (2020-10-10).

514

515 **Study approval**

516 This study was approved by the Institutional Review Board of the Juntendo University School of
517 Medicine Ethics Committee (IRB #21-017, #M21-0017). All participants provided written
518 informed consent for the use of their materials.

519

520 **Author contributions**

521 DH and CA designed and conceptualized the study. DH, AI, and LI conducted experiments. DH
522 analyzed and interpreted the data. YM, MH, HM, YT, and TN provided the clinical information
523 and samples. DH wrote the manuscript. CA reviewed the analysis and manuscript. All authors read
524 and approved the final draft of the manuscript.

525

526 **Acknowledgments**

527 The authors would like to acknowledge all the participants in this study. We are grateful to the
528 entire COVID-19 team at Juntendo University Hospital and thank the Department of Research
529 Support Utilizing Bioresource Bank Juntendo University Graduate School of Medicine for the use
530 of their facilities. We also thank Dr. Scott M.K for critical reading of the manuscript. We also

531 acknowledge financial support from Otsuka Holdings Co., Ltd., Japan, YOKOYAMA Foundation
532 for Clinical Pharmacology (#YRY-2121), and the Japan Society for the Promotion of Science
533 (JSPS)/The Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI
534 Grant-in-Aid for Early-Career Scientists (grant number 21K15888).

535

536 **References**

- 537 1. Mangalmurti N, and Hunter CA. Cytokine Storms: Understanding COVID-19. *Immunity*.
538 2020;53(1):19-25.
- 539 2. Waltuch T, Gill P, Zinns LE, Whitney R, Tokarski J, Tsung JW, et al. Features of COVID-
540 19 post-infectious cytokine release syndrome in children presenting to the emergency
541 department. *Am J Emerg Med*. 2020;38(10):2246 e3- e6.
- 542 3. Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, et al. The N501Y spike substitution
543 enhances SARS-CoV-2 infection and transmission. *Nature*. 2022;602(7896):294-9.
- 544 4. Ulrich L, Halwe NJ, Taddeo A, Ebert N, Schon J, Devisme C, et al. Enhanced fitness of
545 SARS-CoV-2 variant of concern Alpha but not Beta. *Nature*. 2022;602(7896):307-13.
- 546 5. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al.
547 Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. *Cell*.
548 2021;184(13):3426-37 e8.
- 549 6. Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, et al. SARS-CoV-2 spike
550 L452R variant evades cellular immunity and increases infectivity. *Cell Host Microbe*.
551 2021;29(7):1124-36 e11.
- 552 7. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital
553 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2)

- 554 compared with alpha (B.1.1.7) variants of concern: a cohort study. *The Lancet Infectious*
555 *Diseases*. 2022;22(1):35-42.
- 556 8. Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, et al. Enhanced fusogenicity and
557 pathogenicity of SARS-CoV-2 Delta P681R mutation. *Nature*. 2022;602(7896):300-6.
- 558 9. Lippi G, Mattiuzzi C, and Henry BM. Updated picture of SARS-CoV-2 variants and
559 mutations. *Diagnosis (Berl)*. 2021;9(1):11-7.
- 560 10. Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, et al. Antibody
561 responses and correlates of protection in the general population after two doses of the
562 ChAdOx1 or BNT162b2 vaccines. *Nat Med*. 2022;28(5):1072-82.
- 563 11. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA
564 vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
565 *Science*. 2021;374(6572):abm0829.
- 566 12. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos
567 G, et al. Immune responses against SARS-CoV-2 variants after heterologous and
568 homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat Med*. 2021;27(9):1525-9.
- 569 13. Naito T, Tsuchida N, Kusunoki S, Kaneko Y, Tobita M, Hori S, et al. Reactogenicity and
570 immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two
571 doses of BNT162b2 among healthcare workers in Japan: a prospective observational study.
572 *Expert Rev Vaccines*. 2022:1-11.
- 573 14. Goel RR. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and
574 recovered individuals after mRNA vaccination. *Science immunology*. 2021;6(58).

- 575 15. Samanovic MI. Robust immune responses are observed after one dose of BNT162b2
576 mRNA vaccine dose in SARS-CoV-2–experienced individuals. *Science translational*
577 *medicine*. 2022;14(631).
- 578 16. Dan JM. Immunological memory to SARS-CoV-2 assessed for up to 8 months after
579 infection. *Science (American Association for the Advancement of Science)*.
580 2021;371(6529).
- 581 17. Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. Longitudinal
582 analysis shows durable and broad immune memory after SARS-CoV-2 infection with
583 persisting antibody responses and memory B and T cells. *Cell Rep Med*. 2021;2(7):100354.
- 584 18. Bannard O. Germinal centers: programmed for affinity maturation and antibody
585 diversification. *Current opinion in immunology*. 2017;45:21-30.
- 586 19. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally
587 enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*.
588 2021;595(7867):426-31.
- 589 20. Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, et al. Temporal maturation
590 of neutralizing antibodies in COVID-19 convalescent individuals improves potency and
591 breadth to circulating SARS-CoV-2 variants. *Immunity*. 2021;54(8):1841-52 e4.
- 592 21. Walls AC, Sprouse KR, Bowen JE, Joshi A, Franko N, Navarro MJ, et al. SARS-CoV-2
593 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.
594 *Cell*. 2022;185(5):872-80 e3.
- 595 22. Yasuda H, Mori Y, Chiba A, Bai J, Murayama G, Matsushita Y, et al. Resolution of One-
596 Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia
597 in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A

- 598 follow-up Report and Literature Review of Cases With Prolonged Infections. *Clin*
599 *Lymphoma Myeloma Leuk.* 2021;21(10):e810-e6.
- 600 23. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaille J, et al. A longitudinal study of
601 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies
602 and COVID-19 severity. *Cell Mol Immunol.* 2021;18(2):318-27.
- 603 24. Chen Y, Zuiani A, Fischinger S, Mullur J, Atyeo C, Travers M, et al. Quick COVID-19
604 Healers Sustain Anti-SARS-CoV-2 Antibody Production. *Cell.* 2020;183(6):1496-507 e16.
- 605 25. Collier DA, Ferreira I, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune
606 response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature.* 2021;596(7872):417-
607 22.
- 608 26. Romero-Olmedo AJ, Schulz AR, Hochstatter S, Das Gupta D, Virta I, Hirseland H, et al.
609 Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose
610 of BNT162b2 vaccine in previously unresponsive older adults. *Nat Microbiol.*
611 2022;7(2):195-9.
- 612 27. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
613 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science.*
614 2021;372(6538).
- 615 28. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
616 transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature.* 2021;593(7858):266-
617 9.
- 618 29. Jensen B, Luebke N, Feldt T, Keitel V, Brandenburger T, Kindgen-Milles D, et al.
619 Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised
620 patients treated with bamlanivimab in Germany. *Lancet Reg Health Eur.* 2021;8:100164.


- 621 30. Weigang S, Fuchs J, Zimmer G, Schnepf D, Kern L, Beer J, et al. Within-host evolution of
622 SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape
623 variants. *Nat Commun.* 2021;12(1):6405.
- 624 31. Choi B. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *The*
625 *New England journal of medicine.* 2020;383(23):2291-3.
- 626 32. Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, et al. SARS-CoV-2
627 evolution during treatment of chronic infection. *Nature.* 2021;592(7853):277-82.
- 628 33. Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, et al. SARS-CoV-2
629 evolution in an immunocompromised host reveals shared neutralization escape
630 mechanisms. *Cell.* 2021;184(10):2605-17 e18.
- 631 34. Chen Y, Wang J, Liu C, Su L, Zhang D, Fan J, et al. IP-10 and MCP-1 as biomarkers
632 associated with disease severity of COVID-19. *Mol Med.* 2020;26(1):97.
- 633 35. Romagnani S. Cytokines and chemoattractants in allergic inflammation. *Molecular*
634 *Immunology.* 2002;38(12-13):881-5.
- 635 36. Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A, Tateyama M, et al.
636 Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies
637 During Rituximab Maintenance Therapy for Follicular Lymphoma. *Clin Lymphoma*
638 *Myeloma Leuk.* 2020;20(11):774-6.
- 639 37. Martonik D, Parfieniuk-Kowerda A, Rogalska M, and Flisiak R. The Role of Th17
640 Response in COVID-19. *Cells.* 2021;10(6).
- 641 38. Sodeifian F, Nikfarjam M, Kian N, Mohamed K, and Rezaei N. The role of type I interferon
642 in the treatment of COVID-19. *J Med Virol.* 2022;94(1):63-81.

- 643 39. Koyasu S. Type 2 innate immune responses and the natural helper cell Th2-type innate
644 immune responses. *Immunology*. 2011;132(4):475-81.
- 645 40. Pavel AB, Glickman JW, Michels JR, Kim-Schulze S, Miller RL, and Guttman-Yassky E.
646 Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality. *Front*
647 *Genet*. 2021;12:706902.
- 648 41. Liang Z, Zhu H, Wang X, Jing B, Li Z, Xia X, et al. Adjuvants for Coronavirus Vaccines.
649 *Front Immunol*. 2020;11:589833.
- 650 42. Ohashi H, Hishiki T, Akazawa D, Kim KS, Woo J, Shionoya K, et al. Different efficacies
651 of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1
652 and BA.2. *Antiviral Res*. 2022:105372.
- 653 43. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. Characterization and
654 antiviral susceptibility of SARS-CoV-2 Omicron BA.2. *Nature*. 2022;607(7917):119-27.
- 655 44. Takano T, Morikawa M, Adachi Y, Kabasawa K, Sax N, Moriyama S, et al. Distinct
656 immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-
657 CoV-2 mRNA vaccine. *Cell Rep Med*. 2022;3(5):100631.
- 658 45. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, and Wardemann H. Efficient
659 generation of monoclonal antibodies from single human B cells by single cell RT-PCR and
660 expression vector cloning. *J Immunol Methods*. 2008;329(1-2):112-24.

661

662


663 **Figures**



664 **Figure 1**

665 **Figure 1. Serum antibody features in COVID-19 patients during hospitalization.** Graphs
 666 show serum anti-S-RBD IgM (A) and IgG (B) levels for each disease severity. Blue dots indicate
 667 admission and red dots show discharge; the duration of hospitalization is indicated at the bottom
 668 of each panel. Graphs show the correlation between anti-S-RBD IgM or IgG and neutralizing
 669 activity (C) and age, as well as the change in neutralizing activity against the WT strain in patients

670 infected with the WT and VOCs (D). Each dot denotes disease severity, and Spearman's
671 correlation coefficients are shown within the graph. Gray areas indicate a 95% confidence interval
672 (CI) for the total. (E) Dot plot indicates the neutralizing potency against the WT strain by gender.
673 Graphs show the neutralizing activity against WT (F), Kappa (G), and Delta (H) variants at each
674 severity (moderate II is classified by the infected strains). Statistical significances were determined
675 using the Tukey's test and Welch's t-test. All horizontal bars show mean values. Cross, deceased;
676 #, long-term observed healthcare worker. * $p < 0.05$; *** $p < 0.005$; ns, not significant.
677



678

Figure 2

679 **Figure 2. Serum cytokine features of COVID-19 patients infected with the WT strain and**
 680 **VOCs.** Graphs show representative cytokine concentrations for each severity. Blue dots indicate
 681 admission and red dots show discharge. Statistical significances were determined using the
 682 Tukey's test and Welch's t-test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.005$; ns, not significant.

683




Figure 3

684

685 **Figure 3. Correlation analyses of serum cytokines and neutralizing activity against WT in**

686 **COVID-19 patients.** (A) Graphs show Spearman's correlation coefficients of each severity

687 between neutralizing activity and individual cytokine expressions. (B) Graphs show representative


688 correlation plots. Each dot denotes disease severity. Gray areas indicate 95% CI for the total.

689 Statistical significances were determined using Tukey's test. *p < 0.05; ***p < 0.005.

690

698 and recovered individuals are shown in an asymmetric correlation plot. The matrices across three
699 time points for cytokine levels and neutralizing activity, comparing naïve and recovered
700 individuals. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.005$; ns, not significant.

701




702 **Figure 5**

703 **Figure 5. Longitudinal analyses of neutralizing activities and PBMCs in a patient with high**
 704 **neutralizing activity.** (A) Concentration of anti-S-RBD IgM and IgG in the serum of a healthcare
 705 worker (indicated by # in Figure 1) upon infection. (B) Fluctuation of each neutralizing activity
 706 from onset to post-vaccination. (C) Representative FACS plots of cell population are shown in
 707 panels. The numbers indicate the positive rate of each cell population. Graphs show the absolute

708 number of IgG⁺S-RBD⁺ Bmems (D) and the frequency of lymphocyte (E), CD19⁺CD27⁺CD38^{high},
709 and IgG⁺ Bmems (F). Each number indicates the mean.

710



711 **Figure 6**

712 **Figure 6. Longitudinal analysis of cytokine expressions associated with neutralizing activity.**


713 (A) Representative cytokine, chemokine, and interleukin expression fluctuation from onset to post-

714 vaccination. (B) Correlation matrix on the left shows the time of infection from symptom onset to

715 185 days, and that on the right shows the vaccination period from one day before the first

716 vaccination to 36 days after the third vaccination. *p < 0.05; **p < 0.01; ***p < 0.005.

717



718

Figure 7

719 **Figure 7. Affinity maturation of S-RBD-specific memory B-cells after vaccination.** Pie charts
 720 show the distribution of heavy chain genes (A) and light chain genes (B) from onset to post-
 721 vaccination, comparing patients with the recovered individual and a prolonged COVID-19 patient.
 722 (C) Graphs show the number of somatic hypermutations in each antibody gene. Statistical
 723 significances were determined using Tukey's test. (D) Graphs show the distribution of CDR3
 724 length in each antibody gene.